JP5937593B2 - プレガバリンの経口投与剤形 - Google Patents

プレガバリンの経口投与剤形 Download PDF

Info

Publication number
JP5937593B2
JP5937593B2 JP2013522132A JP2013522132A JP5937593B2 JP 5937593 B2 JP5937593 B2 JP 5937593B2 JP 2013522132 A JP2013522132 A JP 2013522132A JP 2013522132 A JP2013522132 A JP 2013522132A JP 5937593 B2 JP5937593 B2 JP 5937593B2
Authority
JP
Japan
Prior art keywords
dosage form
oral dosage
swelling
pregabalin
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013522132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535477A5 (enExample
JP2013535477A (ja
Inventor
メールガン，ドミニク
パエッツ，ジャン
Original Assignee
ラシオファルム ゲーエムベーハー
ラシオファルム ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラシオファルム ゲーエムベーハー, ラシオファルム ゲーエムベーハー filed Critical ラシオファルム ゲーエムベーハー
Publication of JP2013535477A publication Critical patent/JP2013535477A/ja
Publication of JP2013535477A5 publication Critical patent/JP2013535477A5/ja
Application granted granted Critical
Publication of JP5937593B2 publication Critical patent/JP5937593B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013522132A 2010-08-03 2011-08-02 プレガバリンの経口投与剤形 Active JP5937593B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10008104.1 2010-08-03
EP10008104A EP2415460A1 (de) 2010-08-03 2010-08-03 Orale Darreichungsform von Pregabalin
PCT/EP2011/003873 WO2012016683A2 (en) 2010-08-03 2011-08-02 Oral dosage form of pregabalin

Publications (3)

Publication Number Publication Date
JP2013535477A JP2013535477A (ja) 2013-09-12
JP2013535477A5 JP2013535477A5 (enExample) 2016-02-18
JP5937593B2 true JP5937593B2 (ja) 2016-06-22

Family

ID=43216378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013522132A Active JP5937593B2 (ja) 2010-08-03 2011-08-02 プレガバリンの経口投与剤形

Country Status (6)

Country Link
US (1) US20130149253A1 (enExample)
EP (2) EP2415460A1 (enExample)
JP (1) JP5937593B2 (enExample)
KR (1) KR20140003376A (enExample)
CA (1) CA2806752A1 (enExample)
WO (1) WO2012016683A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013100874A1 (en) * 2011-12-19 2013-07-04 Mahmut Bilgic Effervescent pregablin formulation
WO2013109199A1 (en) * 2011-12-19 2013-07-25 Mahmut Bilgic Effervescent pharmaceutical formulations comprising pregabalin and vitamin b12
WO2013100873A1 (en) * 2011-12-19 2013-07-04 Mahmut Bilgic Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer)
MX2013001278A (es) * 2013-01-31 2014-07-30 Miguel Ángel García Pérez Composicion farmaceutica con un sistema bifasico de liberacion inmediata para el control de eventos convulsivos y del dolor.
WO2015114655A2 (en) * 2014-01-21 2015-08-06 Intas Pharmaceuticals Limited Modified release tablet of pregabalin
PL235144B1 (pl) * 2014-06-03 2020-06-01 Univ Medyczny Im Piastow Slaskich We Wroclawiu Sposób wytwarzania tabletki flotacyjnej o przedłużonym oddziaływaniu substancji leczniczych z błoną śluzową żołądka oraz kompozycja farmaceutyczna
CN104561442B (zh) * 2014-10-23 2017-05-31 东莞市佳平装饰材料有限公司 一种核电用347奥氏体不锈钢的制备方法
CN111840239B (zh) * 2014-10-24 2022-11-18 江苏恒瑞医药股份有限公司 一种普瑞巴林缓释制剂
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
KR102039345B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
KR102039344B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 경구용 서방성 삼중정제
WO2022017364A1 (zh) * 2020-07-20 2022-01-27 四川海思科制药有限公司 一种稠合三环γ-氨基酸衍生物的缓释药物制剂及其制备方法
CN112245404A (zh) * 2020-11-02 2021-01-22 成都晶富医药科技有限公司 一种普瑞巴林胶囊及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134674C (en) 1992-05-20 2004-12-21 Richard B. Silverman Gaba and l-glutamic acid analogs for antiseizure treatment
EE200100153A (et) * 1998-09-14 2002-06-17 Ranbaxy Laboratories Limited Kontrollitav ravimiväljutussüsteem ravimite suukaudseks manustamiseks, mis pakub ajalist ja ruumilist kontrolli
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
EP1957052A2 (en) * 2005-10-25 2008-08-20 Pharmascience Inc. A gastric retention drug delivery system
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
CA2635466A1 (en) * 2005-12-29 2007-07-12 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2068844A4 (en) * 2006-09-04 2013-01-23 Panacea Biotec Ltd PROGRAMMABLE RELEASE TECHNIQUE BY FLOATING SYSTEM
WO2008076458A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2010035273A2 (en) * 2008-09-29 2010-04-01 Intec Pharma Ltd. Novel gastroretentive delivery system
US20120065221A1 (en) * 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
EP2736499B1 (en) * 2011-07-26 2016-05-11 Yuhan Corporation Sustained release tablet comprising pregabalin through two-phase release-controlling system

Also Published As

Publication number Publication date
EP2415460A1 (de) 2012-02-08
CA2806752A1 (en) 2012-02-09
WO2012016683A2 (en) 2012-02-09
WO2012016683A3 (en) 2012-05-31
JP2013535477A (ja) 2013-09-12
EP2600831A2 (en) 2013-06-12
KR20140003376A (ko) 2014-01-09
US20130149253A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
JP5937593B2 (ja) プレガバリンの経口投与剤形
CN106943355B (zh) 药物组合物
CA2850468C (en) Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
US8703203B2 (en) Oral dosage form of deferasirox
RS51527B (sr) Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so, postupak za proizvodnju iste i njena primena
US20150272891A1 (en) Dosage forms comprising apixaban and matrix former
KR20190049543A (ko) 붕해가 개선된 경구용 고형 제제 조성물 및 이의 제조 방법
JP5881700B2 (ja) ブロナンセリン経口放出制御型医薬組成物
JP2012503613A (ja) コンパクト化シナカルセット
WO2016062182A1 (zh) 一种普瑞巴林缓释制剂
CN107405311B (zh) 阿普斯特缓释制剂
CA2785684A1 (en) Melt-granulated cinacalcet
JP2017523149A (ja) エドキサバンの医薬組成物
US20120058183A1 (en) Retigabine tablets, preferably having modified release
JP5124286B2 (ja) 徐放性製剤およびその製造方法
JP6854162B2 (ja) 錠剤
EP2190419A1 (en) Multi particulate matrix system containing galantamine
JP7414668B2 (ja) ポリビニルアルコール含有造粒物及び固形製剤
CA3213149A1 (en) A method for the production of gastroretentive compact matrices for the controlled release of active substances and compact matrices thus obtained
WO2014140159A1 (en) Dosage form comprising crizotinib
JP2004339072A (ja) 優れた安定性を有するプラバスタチンナトリウム固形製剤
Vrettos Design, optimisation, in vitro and in vivo evaluation of promising once-a-day tablet formulations of the novel antihypertensive drug MT-1207
WO2008059792A1 (en) Method for production of sustained release tablet
KR20050032510A (ko) 4-아미노-6,7-디메톡시-2-(5-메탄설폰아미도-1,2,3,4-테트라하이드로이소퀴놀-2-일)-5-(2-피리딜)퀴나졸린의 제어방출을 위한 약학적 제형
WO2020249500A1 (en) Stable tablet formulation of nifurtimox and process for producing the same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151217

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20151217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160512

R150 Certificate of patent or registration of utility model

Ref document number: 5937593

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250